MCL1 and plasma cell myeloma: MIK665 is an MCL-1 inhibitor that has been used in phase 1 clinical trials for evaluation of the safety, tolerability, and anti-cancer activity of MIK665 for treatment of refractory or relapsed lymphoma or multiple myeloma (NCT02992483),63 and for treatment of AML and MDS (NCT02979366).64 Our results indicated a significant therapeutic effect of GNA when combined with the MCL-1 inhibitor MIK665 in vitro, suggesting that this combination regimen might be a promising therapeutic strategy for MDS treatment.